Advertisement
Advertisement
Trending on Urology Times
1
Metabolic syndrome frequent during first year of ADT-ARPI therapy for prostate cancer
2
Trial launches of molecular glue degrader plus apalutamide in mCRPC
3
Emanuele Crupi, MD, highlights phase 2 trial of GemFLP in urinary tract adenocarcinomas
4
How ARASEC and ARACOG are reshaping mCSPC treatment choices
5